Skip to content
‹ Back to IndustriesSciences

Fiber Optics Show the Sun in a Whole New Light

While we consistently see the latest in astronomical observations disseminated across numerous news sites, the colossal technological leaps necessary to acquire these images often go unrecognized. While it’s obvious we have come a long way from the early refracting telescopes of a few centuries ago, the capabilities provided by the integration of optical fibers are…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · · Promoted Content
Share
Fiber Optics Show the Sun in a Whole New Light

Key takeaways

01

While we consistently see the latest in astronomical observations disseminated across numerous news sites, the colossal technological leaps necessary to acquire these images often go unrecognized.

02

While it’s obvious we have come a long way from the early refracting telescopes of a few centuries ago, the capabilities provided by the integration of optical fibers are…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

While we consistently see the latest in astronomical observations disseminated across numerous news sites, the colossal technological leaps necessary to acquire these images often go unrecognized. While it’s obvious we have come a long way from the early refracting telescopes of a few centuries ago, the capabilities provided by the integration of optical fibers are incredible, to say the least.

First used for astronomical study in the 1970’s, optical fibers have significantly increased what is possible in spectrography. Scientists are now able to observe multiple objects concurrently using a single spectrograph. These fibers also provide exceedingly high resolution and greater versatility with cables that allow for separation between the observation instruments and telescope.

In fact, thanks to fiber optics, the New Jersey Institute of Technology’s Big Bear Solar Observatory recently made groundbreaking advances in the observation of activity on the sun’s surface. Previously, the observatory’s view was somewhat limited in scope. Now, however, science and research teams can observe simultaneous occurrences like solar flares and coronal mass ejections taking place across a wide field of view. Formerly, these events would have been studied separately, a situation that made it quite difficult to understand the complex dynamics at work.

The NJIT utilizes what is known as a multi-conjugate adaptive optics (MCAO) device to record images. The device takes pictures at three different altitudes to produce a distortion free image. It also allows the observatory to receive images of the entirety of a 20,000-mile-wide sunspot. While it’s taken the team over a decade to perfect the adaptive optics used, the results surely speak for themselves.

Fiberguide is a key supplier for optical fiber products such as IFU’s, 2D array and custom v-groove assemblies.

Fiberguide Industries was selected to build the fiber-optic array for the GHOST (Gemini High-resolution Optical SpecTrograph) in the Gemini South telescope. The array uses cutting-edge construction techniques and Fiberguide’s expertise in building high-quality, high-performance fiber optic subsystems. GHOST will provide two-object plus sky spectroscopy at full wavelength coverage from 363-950nm and resolutions from 50,000 to 75,000.

Each fiber will carry a fraction of the light coming from a stellar object to minimize losses due to atmospheric blurring. Parameters such as fiber optic pointing error and insertion loss are minimized by using proprietary Fiberguide construction techniques and the long history of Fiberguide’s experience building these types of arrays for astronomy, security and data communications. The new instrument will allow for the efficient scanning of the night sky. Click here to learn more about Fiberguide’s line of products.

Read more at fiberguide.com

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte’s December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own outlook but only 41% optimistic about the global economy, a mood the story says the ISPE chairs are programming for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512